Prognostic value of P53 codon 72 polymorphism in invasive cervical cancer in Brazil

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 374-380

  Brenna, S M F ^a   Silva, I D C G ^b   Zeferino, L C ^c   Pereira, J S ^b   Martinez, E Z ^d   Syrjanen K J ^e  

^a HOSPITAL MATERNIDADE LEONOR MENDES DE BARROS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Arginine proline; Cervical cancer; Codon 72; Human papillomavirus (HPV); p53 polymorphism; Prognosis

Indexed keywords

ARGININE; PARAFFIN; PROLINE; PROTEIN P53;

ARTICLE; BRAZIL; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CODON; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; UTERINE CERVIX CANCER;

ARGININE; CODON; DISEASE-FREE SURVIVAL; FEMALE; GENES, P53; HOMOZYGOTE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, GENETIC; UTERINE CERVICAL NEOPLASMS;

EID: 1942476895     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.004     Document Type: Article

References (28)

1. Ferenczy A., Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 3:2002;11-16.
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosh F.X., Kummer J.A., Shah K.V.et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1999;12-19.
3. Syrjänen S.M., Syrjänen K.J. New concepts on the role of human papillomavirus in cell cycle regulation. An. Med. 31:1999;175-187.
4. Storey A., Thomas M., Kalita A., Harwwod C., Gadiol D., Mantovani F.et al. Role of a p53 polymorphism in the development of human papillomavirus- associated cancer. Nature. 393:1998;229-234.
5. Beckman G., Birgander R., Själander A., Saha N., Holmberg P.A., Kivela A.et al. Is p53 polymorphism maintained by natural selection? Hum. Hered. 44:1994;266-270.
6. Zehbe I., Vogliano G., Delius H., Wilander E., Tommasino M. Risk of cervical cancer and geographically variations of human papillomavirus 16 E6 polymorphism. Lancet. 352:1998;1441-1442.
7. Makni H., Franco E.L., Kaiano J., Villa L.L., Labrecque S., Dudly R.et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int. J. Cancer. 87:2000;528-533.
8. Saranath D., Khan Z., Tandle A.T., Dedhia P., Sharma B., Cantractor R.et al. HPV 16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol. Oncol. 86:2002;157-162.
9. Brady C.S., Duggan-Keen M.F., Davidson J.A., Varley J.M., Stern P.L. Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters. J. Gen. Virol. 80:1999;3233-3240.
10. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 19:1999;1092-1100.
11. van Duin M., Snijders P.J.F., Vossen M.T.M., Klaassen E., Voorhorst F., Verheijen R.H.M.et al. Analysis of human papillomavirus type 16 R6 variants in relation to p53codon 72 polymorphism genotypes in cervical carcinogenesis. J. Gen. Virol. 81:2000;317-325.
12. Zehbe I., Voglino G., Wilander E., Delius H., Marongiu A., Edler L.et al. P53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res. 61:2001;608-611.
13. Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T., Heintz A.P.M.et al. Carcinoma of the cervix uteri. Pecorelli S., Benedet J.L., Beller U., Creasman W.T., Heintz A.P., Pettersson F. Journal of Epidemiology and Biostatistics. Annual Report on the Results of Treatment in Gynaecological Cancer. 2001;5-44 Isis Medical Media, Milano.
14. Soulitzis N., Sourvinos G., Sourvinos D.N., Spandidos D.A. P53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 179:2000;175-183.
15. Kleinbaum D.G., Kupper L.L., Morgenstern H. Epidemiologic research: principles and quantitative methods. 1982;Van Nostrand Reinhold, New York.
16. International Agency Research on Cancer (IARC) Cancerbase Cancer Incidence, Mortality and Prevalence Worldwide, Cervix uteri. Version 1.0, no. 5. 2001;IARC Press, Lyon. [cited 24th February 2003. Available from internet: http://www.dep.iarc.fr ].
17. Drummond S.N., De Marco L., Pordeus Ide A., Barbosa A.A., Gómez R.S. TP53 codon 72 polymorphism in oral squamous cell carcinoma. Anticancer Res. 22:2002;3379-3381.
18. Zehbe I., Voglino G., Wilander E., Genta F., Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet. 354:1999;218-219.
19. Agorastos T., Lamobropoulos A.F., Constantinidis T.C., Kotsis A., Bontis J.N. P53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur. J. Cancer Prev. 9:2000;113-118.
20. Arbel-Alon S., Menczer J., Feldman N., Glezerman M., Yeremin L., Friedman E. Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women. Int. J. Gynecol. Cancer. 12:2002;741-744.
21. Radhakrishna P.M., Sreevidya S., Pollock B.H., Jayaprakash P.G., Herman B. Human papillomavirus type 16 E6 and E7 gene variation in Indian cervical cancer. Gynecol. Oncol. 87:2002;268-273.
22. Hildesheim A., Schiffman M., Brinton L.A., Fraumeni J.F. Jr., Herrero R., Bratti M.et al. P53 polymorphism and risk of cervical cancer. Nature. 396:1998;531-532.
23. Helland A., Langerod A., Johnsen H., Olsen A.O., Skovlund E., Borresen-Dale A.L. P53 polymorphism and risk of cervical cancer. Nature. 396:1998;530-531.
24. Giannoudis A., Graham D.A., Southern S.A., Herrington C.S. P53 codon 72 arg/pro polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Int. J. Cancer. 83:1999;66-69.
25. Tachezy R., Mikyshova I., Salakova M., Van Ranst M. Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism. Hum. Genet. 105:1999;564-566.
26. Humbey O., Aubin F., Cairey-Remonnay S., Riethmuller D., Pretet J.L., Fest T.et al. TP53 polymorphism at exon 4 in Caucasian women from eastern France: lack of correlation with HPV status and grade of cervical precancerous lesions. Eur. J. Obstet. Gynecol. Reprod. Biol. 103:2002;60-64.
27. Scarza K., Veress G., Juhasz A., Konya J., Sapy T., Soos G.et al. Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers. Anticancer Res. 20:2000;2161-2167.
28. Ngan H.Y., Liu V.W., Liu S.S., Cheng D.K., Ng T.Y., Wong L.C. Homozygous arginine at codon 72 of p53 has no prognostic significance in cervical cancer. Tumour Biol. 21:2000;135-138.